TEST BANK For Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 6th Edition by Woo & Wright, ISBN13: 9781719648035, All 57 Chapters Covered, Verified Latest Edition

Test Bank Pharmacotherapeutics for Advanced Practice Nurse Prescribers 6e Teri Moser Woo
v v v v v v v v v v v




Woo 1
Pharmacotherapeutics for APN Prescribers, 6e v v v v Ch01


Chapter 1. The Role of the Advanced Practice Nurse as Prescriber
v v v v v v v v v v




MULTIPLE CHOICE v




1. Nurse practitioner prescriptive authority is regulated by:
v v v v v v


A. The National Council of State Boards of Nursing
v v v v v v v


B. The U.S. Drug Enforcement Administration
v v v v


C. The State Board of Nursing for each state
v v v v v v v


D. The State Board of Pharmacy
v v v v




ANS: C v PTS: v 1

2. The benefits to the patient of having an advanced practice registered nurse (APRN) prescriber
v v v v v v v v v v v v v


include:
v


A. Nurses know more about pharmacology than other prescribers because they take it
v v v v v v v v v v v


both in their basic nursing program and in their APRN program.
v v v v v v v v v v v


B. Nurses care for the patient from a holistic approach and include the patient in
v v v v v v v v v v v v v


decision-making regarding their care.
v v v v


C. APRNs are less likely to prescribe narcotics and other controlled substances.
v v v v v v v v v v


D. APRNs are able to prescribe independently in all states, whereas a physician’s
v v v v v v v v v v v


assistant needs to have a physician supervising their practice.
v v v v v v v v v




ANS: B v PTS: v 1

3. Clinical judgment in prescribing includes:
v v v v


A. Factoring in the cost to the patient of the medication prescribed
v v v v v v v v v v


B. Always prescribing the newest medication available for the disease process
v v v v v v v v v


C. Handing out drug samples to poor patients v v v v v v


D. Prescribing all generic medications to cut costs v v v v v v




ANS: A v PTS: v 1

4. The process for choosing an effective drug for a disorder includes:
v v v v v v v v v v


A. Asking the patient what drug they think would work best for them
v v v v v v v v v v v


B. Consulting nationally recognized guidelines for disease management
v v v v v v


C. Prescribing medications that are available as samples before writing a prescription
v v v v v v v v v v


D. Following U.S. Drug Enforcement Administration guidelines for prescribing
v v v v v v v




ANS: B v PTS: v 1

5. Nonintentional nonadherence of drug therapy may occur due to: v v v v v v v v


A. Belief that medication does not work
v v v v v


B. Adverse drug reactions v v


C. Chronic conditions that require daily therapy
v v v v v


D. Forgetfulness or distraction v v




ANS: D v PTS: v 1

, Woo 1
Pharmacotherapeutics for APN Prescribers, 6e v v v v Ch02


Chapter 2. Review of Basic Principles of Pharmacology
v v v v v v v




MULTIPLE CHOICE v




1. A patient’s nutritional intake and laboratory results reflect hypoalbuminemia. This is critical
v v v v v v v v v v v


to prescribing because:
v v v


A. Distribution of drugs to target tissue may be affected. v v v v v v v v


B. The solubility of the drug will not match the site of absorption.
v v v v v v v v v v v


C. There will be less free drug available to generate an effect.
v v v v v v v v v v


D. Drugs bound to albumin are readily excreted by the kidneys.
v v v v v v v v v




ANS: A v PTS: v 1

2. Drugs that have a significant first-pass effect:
v v v v v v


A. Must be given by the enteral (oral) route only
v v v v v v v v


B. Bypass the hepatic circulation v v v


C. Are rapidly metabolized by the liver and may have little, if any, desired action
v v v v v v v v v v v v v


D. Are converted by the liver to more active and fat-soluble forms
v v v v v v v v v v




ANS: C v PTS: v 1

3. The route of excretion of a volatile drug will likely be the:
v v v v v v v v v v v


A. Kidneys
B. Lungs
C. Bile and feces v v


D. Skin

ANS: B v PTS: v 1

4. A major disadvantage to IV administration is that:
v v v v v v v


A. First-pass metabolism is eliminated. v v v


B. Needles and sterility are required. v v v v


C. Absorption of the drug cannot be slowed after administration. v v v v v v v v


D. It is significantly more expensive than other routes.
v v v v v v v




ANS: C v PTS: vv v 1

5. The nurse practitioner (NP) chooses to give cephalexin every 8 hours based on knowledge of
v v v v v v v v v v v v v v


the drug’s:
v v


A. Propensity to go to the target receptor v v v v v v


B. Biological half-life v


C. Pharmacodynamics
D. Safety and side effects v v v




ANS: B v PTS: v 1

6. Deferasirox is a chelating agent used to treat iron overload by binding iron to render it
v v v v v v v v v v v v v v v


biologically inactive. This is best characterized as a(n):
v v v v v v v v

, Woo 2
Pharmacotherapeutics for APN Prescribers, 6e v v v v Ch02


A. Nonreceptor mechanism v


B. Partial agonist v


C. Full agonistv


D. Noncompetitive antagonist v




ANS: A v PTS: v 1

7. The point in time on the drug concentration curve that indicates the first sign of a therapeutic
v v v v v v v v v v v v v v v v


effect is the:
v v v


A. Minimum adverse effect level v v v


B. Peak of action v v


C. Onset of action v v


D. Therapeutic range v




ANS: C v PTS: v 1

8. Phenytoin requires that a trough level be drawn. Peak and trough levels are done:
v v v v v v v v v v v v v


A. When the drug has a wide therapeutic range
v v v v v v v


B. When the drug will be administered for a short time only
v v v v v v v v v v


C. When there is a high correlation between the dose and saturation of receptor sites
v v v v v v v v v v v v v


D. To determine if a drug is in the therapeutic range
v v v v v v v v v




ANS: D v PTS: v 1

9. A laboratory result indicates that the peak level for a drug is above the minimum toxic
v v v v v v v v v v v v v v v


concentration. This means that the:
v v v v v


A. Concentration will produce therapeutic effects. v v v v


B. Concentration will produce an adverse response. v v v v v


C. Time between doses must be shortened.
v v v v v


D. Duration of action of the drug is too long. v v v v v v v v




ANS: B v PTS: v 1

10. Drugs that are receptor agonists may demonstrate what property?
v v v v v v v v


A. Irreversible binding to the drug receptor site v v v v v v


B. Up-regulation with chronic use v v v


C. Desensitization or down-regulation with continuous use v v v v v


D. Inverse relationship between drug concentration and drug action
v v v v v v v




ANS: C v PTS: v 1

11. Drugs that are receptor antagonists, such as beta blockers, may cause:
v v v v v v v v v v


A. Down-regulation of the drug receptor v v v v


B. An exaggerated response if abruptly discontinued
v v v v v


C. Partial blockade of the effects of agonist drugs
v v v v v v v


D. An exaggerated response to competitive drug agonists
v v v v v v




ANS: B v PTS: v 1

, Woo 3
Pharmacotherapeutics for APN Prescribers, 6e v v v v Ch02


12. Factors that affect gastric drug absorption include:
v v v v v v


A. Liver enzyme activity v v


B. Protein-binding properties of the drug molecule v v v v v


C. Lipid solubility of the drug v v v v


D. Ability to chew and swallow v v v v




ANS: C v PTS: v 1

13. Drugs administered via IV:
v v v


A. Need to be lipid soluble in order to be easily absorbed
v v v v v v v v v v


B. Begin distribution into the body immediately v v v v v


C. Are easily absorbed if they are nonionized
v v v v v v


D. May use pinocytosis to be absorbed
v v v v v




ANS: B v PTS: v 1

14. When a medication is added to a regimen for a synergistic effect, the combined effect of the
v v v v v v v v v v v v v v v v


drugs is:
v v


A. The sum of the effects of each drug individually
v v v v v v v v


B. Greater than the sum of the effects of each drug individually
v v v v v v v v v v


C. Less than the effect of each drug individually
v v v v v v v


D. Not predictable, as it varies with each individual
v v v v v v v




ANS: B v PTS: v 1

15. Which of the following statements about bioavailability is true?
v v v v v v v v


A. Bioavailability issues are especially important for drugs with narrow therapeutic v v v v v v v v v


ranges or sustained-release mechanisms.
v v v v


B. All brands of a drug have the same bioavailability.
v v v v v v v v


C. Drugs that are administered more than once a day have greater bioavailability than
v v v v v v v v v v v v


drugs given once daily.
v v v v


D. Combining an active drug with an inert substance does not affect bioavailability.
v v v v v v v v v v v




ANS: A v PTS: v 1

16. Which of the following statements about the major distribution barriers (blood–brain or fetal–
v v v v v v v v v v v v


placental) is true?
v v v


A. Water soluble and ionized drugs cross these barriers rapidly.
v v v v v v v v


B. The blood–brain barrier slows the passage of many drugs into and out of brain
v v v v v v v v v v v v v


cells.
v


C. The fetal–placental barrier protects the fetus from drugs taken by the mother.
v v v v v v v v v v v


D. Lipid-soluble drugs do not pass these barriers and are safe for pregnant women. v v v v v v v v v v v v




ANS: B v PTS: v 1

17. Drugs are metabolized mainly by the liver via phase I or phase II reactions. The purpose of
v v v v v v v v v v v v v v v v


both of these types of reactions is to:
v v v v v v v v


A. Inactivate prodrugs before they can be activated by target tissues v v v v v v v v v